Status:
RECRUITING
Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT
Lead Sponsor:
Peking University First Hospital
Conditions:
Carcinoma, Renal Cell
Diagnostic Imaging
Eligibility:
All Genders
18-85 years
Brief Summary
This study aims to develop and validate a contrast-enhanced CT-based deep-learning model for automatic and accurate preoperative discrimination between T1-T2 and T3 renal cell carcinoma. By quantifyin...
Eligibility Criteria
Inclusion
- Histopathologically confirmed renal cell carcinoma on postoperative specimen.
- Preoperative contrast-enhanced CT performed at our institution with slice thickness ≤ 1 mm and complete DICOM datasets.
- Postoperative pathologic staging clearly defined as pT1a-T2b or pT3a.
- CT image quality deemed adequate for analysis.
Exclusion
- 1\. Pathologic subtype other than RCC. 2. Images with severe artifacts.
Key Trial Info
Start Date :
September 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT07166445
Start Date
September 1 2024
End Date
December 1 2027
Last Update
September 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University First Hospital, Beijing,
Beijing, China